Abstract
Purpose Prostate-specific membrane antigen (PSMA) PET/CT has shown to be more sensitive and accurate than conventional imaging. Visual interpretation of the images causes both intra- and inter-reader disagreement and there is therefore a need for objective methods to analyze the images. The aim of this study was to develop an artificial intelligence (AI) tool for PSMA PET/CT and to evaluate the influence of the tool on inter-reader variability.
Approach We have recently trained AI tools to automatically segment organs, detect tumors, and quantify volume and tracer uptake of tumors in PET/CT. The primary prostate gland tumor, bone metastases, and lymph nodes were analyzed in patients with prostate cancer. These studies were based on non-PSMA targeting PET tracers. In this study an AI tool for PSMA PET/CT was developed based on our previous AI tools. Letting three physicians analyze ten PSMA PET/CT studies first without support from the AI tool and at a second occasion with the support of the AI tool assessed the influence of the tool. A two-sided sign test was used to analyze the number of cases with increased and decreased variability with support of the AI tool.
Results The range between the physicians in prostate tumor total lesion uptake (TLU) decreased for all ten patients with AI support (p=0.002) and decreased in bone metastases TLU for nine patients and increased in one patient (p=0.01). Regarding the number of detected lymph nodes the physicians agreed in on average 72% of the lesions without AI support and this number decreased to 65% with AI support.
Conclusions Physicians supported by an AI tool for automated analysis of PSMA-PET/CT studies showed significantly less inter-reader variability in the quantification of primary prostate tumors and bone metastases than when performing a completely manual analysis. A similar effect was not found for lymph node lesions. The tool may facilitate comparisons of studies from different centers, pooling data within multicenter trials and performing meta-analysis. We invite researchers to apply and evaluate our AI tool for their PSMA PET/CT studies. The AI tool is therefore available upon reasonable request for research purposes at www.recomia.org.
Competing Interest Statement
Edenbrandt reports grants from EXINI diagnostics AB, Lund, Sweden outside the submitted work until August 2020. Edenbrandt was employed as Scientific Director by EXINI Diagnostics AB (Lund, Sweden) until May 2020. Borrelli works as consultant for EXINI Diagnostics AB (Lund, Sweden).
Funding Statement
The study was financed by grants from the Knut and Alice Wallenberg foundation, the Medical Faculty at Lund University, Region Skane and the Swedish state under the agreement between Swedish government and the county councils, the ALF-agreement (ALFGBG-720751).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the principles expressed in the Declaration of Helsinki, and approved by the local research ethics committee at Lund University (#2016/193 and #2018/753). All patients provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The AI tool and data presented in this study is available upon reasonable request for research purposes at www.recomia.org.
